UBS raised the firm’s price target on PTC Therapeutics (PTCT) to $71 from $47 and keeps a Buy rating on the shares. PTC Therapeutics on Monday announced a global licensing and collaboration agreement ...
Citi raised the firm’s price target on PTC Therapeutics (PTCT) to $32 from $26 and keeps a Sell rating on the shares. The firm updated the company’s model to reflect the Novartis collaboration, which ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
Investor's Business Daily on MSN4h
PTC Getting Closer To Key Technical BenchmarkRating, from 69 to 73.Please watch the video at Investors.com - Find Top Growth Stocks With The IBD Screen Of The DayThis ...
The results of CardinALS showed utreloxastat failed to meet its main and secondary goals, including several disease-related ...
PTC Therapeutics, Inc. (PTCT) stock saw a modest uptick, ending the day at $52.07 which represents a slight increase of $8.19 or 18.66% from the prior close of $43.88. The stock opened at $52.08 and ...
Among the top beneficiaries identified by ICICI Securities are Bharat Electronics Ltd. (BEL), Astra Microwave Products Ltd., ...
Toronto is looking to cap the number of rideshare drivers operating services like Uber and Lyft in the city, but a prominent ...
ICICI Securities said PTC Industries may benefit in engine overhaul, as the company has executed an MoU with HAL’s Koraput ...
The development of Codebeamer Copilot builds on Volkswagen Group’s adoption of Codebeamer to support software development ...
Multiple cameras were live this morning when a man approached Akali Dal chief Sukhbir Singh Badal at the Golden Temple gate ...
Consumption of renewable diesel on the U.S. East Coast has been on the rise, the U.S. Energy Information Administration said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback